24 results
F-3
IPA
ImmunoPrecise Antibodies Ltd
10 Jul 23
Shelf registration (foreign)
7:04pm
of the registration fee pursuant to Rule 457(o) of the Securities Act.
Table 2: Fee Offset Claims and Sources
Registrant or
Filer Name
Form or Filing
Type
File … Number
Initial Filing
Date
Filing Date
Fee Offset
Claimed
Security Type
Associated
with Fee Offset
Claimed
Security Title
Associated
with Fee
Offset
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
7 Jul 23
Immunoprecise Antibodies LTD. 6-K
8:36am
April 30, 2022. The increased net loss is the result of an increase in gross profit of $0.6 million, offset by an increase in research and development
40-F
2022 FY
EX-99.3
IPA
ImmunoPrecise Antibodies Ltd
29 Jul 22
Annual report (Canada)
9:04am
, partially offset by higher professional fees and consulting fees.
IMMUNOPRECISE ANTIBODIES LTD.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE YEAR ENDED
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
14 Apr 22
Current report (foreign)
10:18am
or any Contract with a Taxing Authority;
5.24.13.2 has obtained, whether by way of payment, credit or offset, any deduction or Tax Receivable to which … , whether by way of payment, credit or offset, any deduction or Tax Receivable to which it was, to the Knowledge of the IDF Vendors, not entitled under
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
12 Apr 22
Material Change Report
1:41pm
, compared to $717,716 for the three months ended January 31, 2020. This increase is related to the increased gross profit offset by the costs … and subsidy income compared to the prior period offset by Nasdaq costs.
Cash Position. As of January 31, 2021, the Company had cash on hand of $15,720,057
6-K
EX-99.1
306 1j6jhu0ny
16 Mar 22
FY22 Q3 6-K
8:00am
6-K
EX-99.1
64wuoj4vl7h84mq
13 Dec 21
Ipa FY22 Q2 6-K
8:57am
6-K
EX-99.1
qrht kxxu
28 Jul 21
Immunoprecise Antibodies LTD. 6-K
9:01am
40-F
EX-99.3
t43nvjohpz87sm zc7
28 Jul 21
Annual report (Canada)
8:01am
6-K
EX-99.1
us5sxpa29qfbwy
18 Mar 21
Current report (foreign)
6:05am
6-K
EX-99.1
ltph z0cv
18 Mar 21
Immunoprecise Antibodies LTD. Form 6-K
12:00am
6-K
EX-99.2
oz552p2xk7sebl
3 Feb 21
Condensed Interim Consolidated Financial Statements
4:28pm
40FR12B/A
EX-99.136
pek7qpp
22 Dec 20
Initial registration of securities (Canada) (amended)
11:05am
40FR12B/A
EX-99.135
2z39oa rzvmnjg2zhp
22 Dec 20
Initial registration of securities (Canada) (amended)
11:05am
F-10
EX-4.3
b3dclh2t4hanmcm
9 Nov 20
Registration of securities (Canada)
8:18am
F-10
EX-4.5
ric5tuzzvlb77
9 Nov 20
Registration of securities (Canada)
8:18am
40FR12B/A
EX-99.96
mczb0774mn 9xrqln
2 Oct 20
Initial registration of securities (Canada) (amended)
2:24pm
40FR12B
EX-99.30
x2qju
16 Sep 20
Initial registration of securities (Canada)
4:06pm
40FR12B
EX-99.83
204ygqzgtq19
16 Sep 20
Initial registration of securities (Canada)
4:06pm
40FR12B
EX-99.49
rsbox4m
16 Sep 20
Initial registration of securities (Canada)
4:06pm